Seagen has a new suitor as Pfizer talks begin
After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Cystic fibrosis developers take a deep breath
*please scroll down for all the latest news*
